Canada Pension Plan Investment Board Exelixis, Inc. Transaction History

Canada Pension Plan Investment Board

$96.3 Billion
Q2 2024

A detailed history of Canada Pension Plan Investment Board transactions in Exelixis, Inc. stock. As of the latest transaction made, Canada Pension Plan Investment Board holds 637,800 shares of EXEL stock, worth $17 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

637,800

Previous 588,100 8.45%

Holding current value

$17 Million

Previous $14 Million 2.69%

% of portfolio

0.01%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$20.34 - $23.73 $1.01 Million - $1.18 Million	49,700 Added 8.45%	637,800 $14.3 Million
Q1 2024 May 14, 2024	BUY	$20.17 - $23.93 $1.17 Million - $1.39 Million	57,900 Added 10.92%	588,100 $14 Million
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $6.07 Million - $7.61 Million	315,300 Added 146.72%	530,200 $12.7 Million
Q3 2023 Nov 09, 2023	BUY	$19.04 - $22.74 $22,848 - $27,287	1,200 Added 0.56%	214,900 $4.7 Million
Q2 2023 Aug 09, 2023	SELL	$18.17 - $20.48 $1.25 Million - $1.4 Million	-68,600 Reduced 24.3%	213,700 $4.08 Million
Q1 2023 May 12, 2023	SELL	$16.3 - $19.41 $932,441 - $1.11 Million	-57,205 Reduced 16.85%	282,300 $5.48 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $1.74 Million - $2.02 Million	116,300 Added 52.1%	339,505 $5.45 Million
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $2.21 Million - $3.14 Million	140,800 Added 170.86%	223,205 $3.5 Million
Q2 2022 Aug 12, 2022	BUY	$17.44 - $23.16 $819,680 - $1.09 Million	47,000 Added 132.75%	82,405 $1.72 Million
Q1 2022 May 13, 2022	BUY	$17.03 - $22.67 $459,844 - $612,135	27,002 Added 321.34%	35,405 $802,000
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $7,302 - $10,086	461 Added 5.8%	8,403 $154,000
Q3 2021 Nov 15, 2021	SELL	$16.3 - $21.14 $96,675 - $125,381	-5,931 Reduced 42.75%	7,942 $168,000
Q2 2021 Aug 16, 2021	SELL	$17.95 - $25.56 $1.4 Million - $1.99 Million	-77,905 Reduced 84.88%	13,873 $252,000
Q1 2021 May 17, 2021	BUY	$20.53 - $25.22 $260,997 - $320,621	12,713 Added 16.08%	91,778 $2.07 Million
Q4 2020 Feb 17, 2021	BUY	$18.39 - $24.8 $467,179 - $630,019	25,404 Added 47.34%	79,065 $1.59 Million
Q3 2020 Nov 12, 2020	SELL	$20.67 - $26.94 $3.98 Million - $5.18 Million	-192,426 Reduced 78.19%	53,661 $1.31 Million
Q2 2020 Aug 14, 2020	BUY	$16.46 - $27.42 $895,835 - $1.49 Million	54,425 Added 28.4%	246,087 $5.84 Million
Q1 2020 May 13, 2020	BUY	$14.46 - $21.8 $1.16 Million - $1.74 Million	80,019 Added 71.67%	191,662 $3.3 Million
Q4 2019 Feb 14, 2020	BUY	$15.15 - $18.89 $1.69 Million - $2.11 Million	111,643 New	111,643 $1.97 Million
Q3 2019 Nov 12, 2019	SELL	$17.68 - $22.65 $9.28 Million - $11.9 Million	-524,867 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$18.93 - $24.75 $5.47 Million - $7.16 Million	-289,213 Reduced 35.53%	524,867 $11.2 Million
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $1.05 Million - $1.33 Million	53,680 Added 7.06%	814,080 $19.4 Million
Q4 2018 Feb 06, 2019	BUY	$13.65 - $21.8 $1.63 Million - $2.61 Million	119,600 Added 18.66%	760,400 $15 Million
Q3 2018 Nov 09, 2018	BUY	$15.87 - $22.4 $1.69 Million - $2.38 Million	106,400 Added 19.91%	640,800 $11.4 Million
Q2 2018 Aug 07, 2018	SELL	$18.56 - $22.45 $6.03 Million - $7.3 Million	-325,000 Reduced 37.82%	534,400 $11.5 Million
Q1 2018 May 14, 2018	BUY	$22.15 - $31.89 $9.74 Million - $14 Million	439,600 Added 104.72%	859,400 $19 Million
Q4 2017 Feb 14, 2018	BUY	$24.23 - $30.93 $1.16 Million - $1.48 Million	47,900 Added 12.88%	419,800 $12.8 Million
Q3 2017 Oct 30, 2017	BUY	$23.35 - $29.24 $7.61 Million - $9.52 Million	325,700 Added 704.98%	371,900 $9.01 Million
Q2 2017 Jan 31, 2018	BUY	N/A	46,200	46,200 $1.14 Million

Others Institutions Holding EXEL

# of Institutions

460

Shares Held

240M

Call Options Held

2.04M

Put Options Held

1.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $8.57B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Canada Pension Plan Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on Canada Pension Plan Investment Board with notifications on news.

Account

Canada Pension Plan Investment Board Exelixis, Inc. Transaction History